Capricor Therapeutics’ (CAPR) “Neutral” Rating Reiterated at Roth Capital

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “neutral” rating reissued by Roth Capital in a research note issued to investors on Friday, Benzinga reports. They presently have a $10.50 price objective on the biotechnology company’s stock, up from their previous price objective of $7.00. Roth Capital‘s target price points to a potential upside of 12.41% from the company’s previous close.

Several other research firms have also recently commented on CAPR. Maxim Group cut Capricor Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. Piper Sandler upgraded Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a report on Tuesday, September 1st. Ladenburg Thalmann & Co. Inc. downgraded shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, July 30th. HC Wainwright downgraded shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, July 27th. Finally, Oppenheimer restated an “outperform” rating on shares of Capricor Therapeutics in a report on Thursday, October 8th. Five research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $30.09.

Capricor Therapeutics Stock Down 8.8%

CAPR opened at $9.34 on Friday. Capricor Therapeutics has a twelve month low of $2.96 and a twelve month high of $40.37. The company has a fifty day moving average of $8.10 and a 200-day moving average of $19.92. The stock has a market cap of $543.09 million, a PE ratio of -3.52 and a beta of 0.80.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Tuesday, November 10th. The biotechnology company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.29). Sell-side analysts anticipate that Capricor Therapeutics will post -1.71 EPS for the current fiscal year.

Hedge Funds Weigh In On Capricor Therapeutics

A number of large investors have recently modified their holdings of the company. Russell Investments Group Ltd. raised its holdings in shares of Capricor Therapeutics by 21.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 17,326 shares of the biotechnology company’s stock worth $164,000 after acquiring an additional 3,036 shares during the last quarter. Commonwealth Equity Services LLC boosted its stake in Capricor Therapeutics by 151.7% during the 3rd quarter. Commonwealth Equity Services LLC now owns 67,402 shares of the biotechnology company’s stock valued at $638,000 after purchasing an additional 40,627 shares during the last quarter. VestGen Advisors LLC acquired a new position in Capricor Therapeutics during the 3rd quarter valued at about $191,000. Oppenheimer & Co. Inc. boosted its stake in Capricor Therapeutics by 169.1% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 203,781 shares of the biotechnology company’s stock valued at $1,930,000 after purchasing an additional 128,067 shares during the last quarter. Finally, SBI Securities Co. Ltd. increased its holdings in Capricor Therapeutics by 834.6% during the 3rd quarter. SBI Securities Co. Ltd. now owns 26,310 shares of the biotechnology company’s stock worth $249,000 after purchasing an additional 23,495 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics is a biotechnology company developing cell- and exosome-based therapies for serious diseases. Its research focuses on using these technologies to address conditions with limited treatment options. The company’s leading program is deramiocel, also known as CAP-1002, an investigational therapy made from donor-derived cardiac cells. Capricor is developing it for Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness. Capricor is also advancing an exosome-based technology platform for potential therapeutic applications.